Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200?

The setup around Merck (NYSE:MRK | MRK Price Prediction) shares heading into September is unusual for a mega-cap pharma. Wall Street’s consensus target sits below the current stock price, meaning analysts would have to raise their numbers for $200 to come into view. There’s a lot to consider in the near future: a dense stretch of FDA decision deadlines, known as PDUFA dates after the Prescription Drug User Fee Act, arrives between September and late October.

Merck stock was up 19% over the past month to $155.99, outpacing the iShares Biotechnology ETF (NASDAQ:IBB), which was up 15% over the same span to $216.16. Merck shares were up 45% year to date (YTD) through Monday’s close, one of the strongest large-cap pharma runs of the year.

Meanwhile, Moderna (NASDAQ:MRNA) stock was up 157% over the past month through Monday’s close, to $138.89, as Merck’s cancer vaccine partner captured its own share of pre-ESMO enthusiasm. The two companies’ fates are increasingly linked through the intismeran autogene program.

Catalyst Calendar Drives the Case

The near-term case for Merck stock reaching $200 depends on a compressed run of regulatory and clinical events this fall. WINREVAIR’s supplemental application carries a PDUFA date of September 21, followed by WELIREG combined with Lenvima on October 4. Ifinatamab deruxtecan has a PDUFA date of October 10, giving Merck three separate label events to open the fourth quarter.

Merck’s biggest data drop sits at month’s end. The full dataset for intismeran autogene, the personalized cancer vaccine Merck is developing with Moderna, is expected at the ESMO conference in Madrid, running October 23 to 27. Moderna management expects the Phase 3 adjuvant melanoma interim analysis in the second half of 2026, and a positive result could unlock estimate revisions across Merck’s oncology franchise. Moderna is already building dedicated commercial manufacturing capacity in Massachusetts for a potential launch alongside Merck.

KEYTRUDA Engine and the Bear Case

Merck’s Q1 2026 results underscored the operating engine behind the rally. KEYTRUDA franchise sales rose 12% to $8.03 billion, and WINREVAIR jumped 88% to $525 million on continued pulmonary arterial hypertension demand. Merck reported a non-GAAP loss of $1.28 per share, narrower than the $1.47 loss consensus expected, with the shortfall driven by a $9 billion charge from the Cidara Therapeutics acquisition; it marked Merck’s fourth consecutive quarter topping consensus EPS.

Management raised its full-year 2026 guidance to sales of $65.8 billion to $67 billion and non-GAAP EPS of $5.04 to $5.16. On the Q2 2026 call, Merck CEO Robert Davis described the KEYTRUDA loss-of-exclusivity period as “more of a hill than a cliff,” adding that investors will see “a shallow dip with a fast return back to growth.” Davis also flagged a commercial opportunity greater than $70 billion from over 20 new products in development.

The bear case still carries weight. KEYTRUDA accounts for nearly half of Merck’s pharmaceutical revenue and faces a patent cliff, GARDASIL sales in China have fallen to zero, and the pending Terns Pharmaceuticals deal adds roughly $5.8 billion in one-time charges. Larger peer Pfizer (NYSE:PFE) is building its own oncology and obesity pipeline, and mRNA oncology developer BioNTech SE (NASDAQ:BNTX) is advancing pembrolizumab combination studies that could reshape the next wave of immuno-oncology, offering alternative exposure to the same theme for anyone hedging single-name risk.

What Could Push MRK to $200

The move from here to $200 needs Merck to deliver, plain and simple, though it would certainly also help if analysts lift their MRK price targets. Momentum alone can’t close the gap given that Merck stock trades near 56x forward earnings against forward EPS of $5.74. A clean sweep on the September and October PDUFA calendar combined with a compelling intismeran readout at ESMO could reset consensus on Merck’s post-KEYTRUDA growth curve and shift the analyst target higher.

Traders can watch for a clean separation in the melanoma vaccine data and a WINREVAIR label expansion that clears without concessions. Merck’s beta of 0.211 keeps single-day moves in the stock modest, so any repricing toward $200 likely comes in incremental steps. A predicted price of $260.48 from quantitative models sits far above the analyst target of $147.77, and the two views need to converge for $200 to look like a base case.

Investors should size their positions with the fall calendar treated as event risk in both directions. A miss on any of the four catalysts, particularly a mixed melanoma readout at ESMO, could invite profit-taking after the YTD run. Position sizing that keeps their exposure balanced against the KEYTRUDA cliff and Terns-related charges leaves room to add on any pullback into the ESMO print.

Contact [email protected] for any questions or corrections.